News Center
SciBrunch Therapeutics Completes Over 35 Million Pre-A Round Financing, Totaling 65 Million in Two Recent RoundsSciBrunch Therapeutics announced the completion of an oversubscribed Pre-A round financing of over $35 million.
First Patient In! SciBrunch Initiates Phase I Clinical Trial of Highly Selective PARP1 Inhibitor SPR1020SciBrunch Therapeutics announced that the Phase I/II clinical trial of SPR1020 for advanced solid tumors, co-led by the Cancer Hospital of the Chinese Academy of Medical Sciences and Harbin Medical
SciBrunch Therapeutics Completes Over RMB 200 Million Angel Round Financing, Focused on Innovative Small-Molecule Oncology DrugsSciBrunch Therapeutics recently announced the completion of an angel round financing of over RMB 200 million. The round was co-led by BioTrack Capital and HanKang Capital, with participation from Elik
- 1